组蛋白去乙酰化酶抑制剂治疗皮肤T-细胞淋巴瘤的临床研究进展
摘要
组蛋白去乙酰化酶抑制剂（histone deacetylase inhibitors，HDACI）作为一类非细胞毒性新型抗肿瘤的靶向治疗药物备受关注，其抗肿瘤应用日益广泛。尤其对皮肤T-细胞淋巴瘤（cutaneous T cell lymphoma，CTCL）的临床疗效显著，目前已有多种药物进入临床试验阶段。被美国食品药品监督管理局（FDA）批准上市用于治疗CTCL的4种药物中有异羟肟酸类Vorinostat（SAHA）和环四肽类Romidepsin为HDACI。
出处
《中国临床研究》
CAS
2013年第3期288-290,共3页
Chinese Journal of Clinical Research
参考文献18
-
1Rangwala S, Zhang C, Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas [ J ]. Future Med Chem, 2012,4 (4) : 471 - 486.
-
2Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome [ J ]. J Clin On- col,2010,28 ( 14 ) : 2365 - 2372.
-
3Duvic M. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies [ J ]. Oncology (winiston Park ), 2007,21 (2 Suppl 1 ) :33 -40.
-
4Kelly WK,O'Connor OA,Krug LM,et al. Phase I study of an oral histone deacetylase inhibitor, subereylanilide hydroxamic acid, in patients with advanced cancer [ J ]. J Clin Oneol, 2005,23 ( 17 ) : 3923 - 3931.
-
5O'Connor OA, Heaney ML,Schwartz L,et al. Clinical experience with intravenous and oral formulations of the novel histone deacety- lose inhibitor suberoylanilide hydroxamic acid in patients with ad- vanced hematologic malignancies [ J ]. J Clin Oncol, 2006,24 ( 1 ) : 166 - 173.
-
6Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat ( sube- roylanilide hydroxamic acid, SAHA ) for refractory cutaneous T-cell lymphoma(CTCL) [ J]. Blood,2007,109 ( 1 ) :31 - 39.
-
7Olsen EA, Kim YH, Kuzel TM, et al. Phase lib muhicenter trial ofvorinostat in patients with persistent, progressive, or treatment refrac- tory cutaneous T-cell lymphoma[ J ]. J Clin Oncol, 2007,25 (21) : 3109 -3115.
-
8Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinical benefit of vorinastat in patients with ad- vanced cutaneous T-cell lymphoma [ J ]. Clin Lymphoma Myeloma, 2009,9(6) :412 -416.
-
9Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetyla- tion,depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report [ J ]. Blood,2001,98 ( 9 ) : 2865 - 2868.
-
10Piekarz RL, Frye R,Turner M, et al. Phase II multi-Institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma[ J]. J Clin Oncol,2009,27 (32) :5410-5417.
-
12009年11月份美国FDA批准的NDA[J].国外药讯,2009(12):6-7.
-
2FDA批准抗周围T-细胞淋巴瘤新药Istodax[J].齐鲁药事,2011,30(8):439-439.
-
3张会来,吕慧娟,王华庆.组蛋白去乙酰化酶抑制剂治疗T细胞淋巴瘤的作用机制及临床研究进展[J].中国肿瘤临床,2014,41(19):1213-1216. 被引量：1
-
4郭亚收(综述),王志平(审校).HDACi对TCC和前列腺癌治疗作用的研究进展[J].国际泌尿系统杂志,2010,30(3):323-327.
-
5朱京丽,钟毓斌,秦林林.4例皮肤T－细胞淋巴瘤的电子线全身照射[J].中日友好医院学报,1995,9(1):33-35. 被引量：1
-
6申莹莹,苏小桃,欧军,何俊.二甲双胍联合异羟肟酸对骨肉瘤细胞增殖凋亡的影响[J].中南医学科学杂志,2016,44(1):11-15. 被引量：4
-
7组蛋白去乙酰化酶抑制剂Romidepsin在美国获准用于治疗皮肤T细胞淋巴瘤[J].药学进展,2010,34(4):191-191.
-
8毕艳静,宁澄清,余聂芳.基于HDAC抑制剂设计的多靶点抗癌药物的研究进展[J].肿瘤药学,2014,4(2):86-96. 被引量：2
-
9江余祺,张剑,李晓杨,徐文方.Romidepsin合成路线图解[J].中国药物化学杂志,2013,23(2):157-160. 被引量：2
-
10隋娜,郭长彬.romidepsin(Istodax)[J].中国药物化学杂志,2010,20(3):239-239. 被引量：1
